First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.


TRV027 is a novel β-arrestin biased peptide ligand of the angiotensin II type 1 receptor (AT1R). The compound antagonizes G protein coupling while simultaneously stimulating β-arrestin-mediated signaling. In preclinical studies, TRV027 reversibly reduced blood pressure while preserving renal function in a dog tachypaced heart failure model and stimulating… (More)
DOI: 10.1002/jcph.111


  • Presentations referencing similar topics